Trial Profile
A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Acronyms ESSENCE Trial; ESSENCE-1
- Sponsors Novaliq
- 02 May 2023 According to a Novaliq media release, data from pooled analysis from ESSENCE-1 and ESSENCE-2 will be presented during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting 2023.
- 28 Apr 2021 According to a Novaliq media release, results from this trial has been published in Cornea: The Journal of Cornea and External Disease.
- 23 Oct 2018 Status changed from active, no longer recruiting to completed.